Orencia (abatacept) / Ono Pharmaceutical, BMS, Simcere - LARVOL DELTA

BIMEKIZUMAB-ASSOCIATED ILEOCOLITIS MIMICKING INFLAMMATORY BOWEL DISEASE IN A PATIENT WITH ANKYLOSING SPONDYLITIS (UEGW 2026) - "Vedolizumab is used for IBD, while rheumatology-focused agents include IL-17 inhibitors, IL-6 receptor antagonists such as tocilizumab and sarilumab, and abatacept, which inhibits T-cell co-stimulation by blocking the CD80/86-CD28 interaction...We report acute ileocolitis shortly after initiation of bimekizumab, a dual IL-17A/IL-17F inhibitor.A 45-year-old man with ankylosing spondylitis previously treated with infliximab, adalimumab, and golimumab, was switched to bimekizumab...The close temporal relationship to treatment initiation and rapid clinical and biochemical resolution after drug withdrawal strongly support a drug-induced mechanism. Early recognition, exclusion of infection, and prompt discontinuation are essential for gastroenterologists and rheumatologists and may help avoid unnecessary escalation to IBD-directed therapy."

Clinical • Ankylosing Spondylitis • Axial Spondyloarthritis • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Hodgkin Lymphoma • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • CD80 • IL23A • IL6

The many faces of atrioventricular block in myocarditis: a case series and proposed clinical strategy highlighting cardiovascular magnetic resonance-guided diagnosis, device selection, and disease monitoring. (PubMed, Eur Heart J Case Rep) - "Cardiac magnetic resonance imaging was essential in the identification of underlying myocarditis, offering insights in the disease course, and may therefore be used as an adjunctive tool for device selection. However, mismatch between CMR findings and AV conduction disorders may occur and warrants further investigation."

Journal • Cardiovascular • CNS Disorders • Fibrosis • Immunology • Inflammation

CD80 as an Important Immune Mediator and Therapeutic Target in Atherosclerosis. (PubMed, Int J Mol Sci) - "Molecular imaging agents targeting CD80/CD86, repurposed CTLA-4-Ig biologics such as abatacept, and antigen-specific tolerogenic dendritic cell strategies together constitute an emerging translational pipeline. To our knowledge, this is the first review to integrate CD80's structural and receptor pharmacology with its cellular sources in the plaque, preclinical genetic and pharmacological evidence, human plaque and biomarker data, molecular imaging approaches, and checkpoint inhibitor-associated cardiovascular toxicity within a single translational framework. This review synthesizes the structural biology, cellular sources, preclinical genetics, human plaque and biomarker data, and therapeutic and diagnostic implications of CD80 as an immune mediator and candidate therapeutic target in atherosclerosis."

IO biomarker • Journal • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • Oncology • CD80 • CD86 • PD-L1

A Decade of Progress Towards Safer and More Broadly Applicable Allogeneic Stem Cell Transplantation (ASH 2026) - "Hany Elmariah (Stanford) presenting "New Standards in GVHD Prophylaxis: Towards a Future Without GVHD," which examines the latest advances in prophylactic strategies, including Orca-T, abatacept, and post-transplant cyclophosphamide (PTCy), and how these approaches are reshaping the standard of care...These include ruxolitinib and mesenchymal stromal cells (MSCs) for acute GVHD (with pediatric indications), as well as belumosudil, ruxolitinib, and axatilimab for chronic GVHD, and how they are improving outcomes for patients with steroid-refractory disease...Holtan's talk, "A Donor for All: Increasing Access and Improving Outcomes," which addresses expanding donor options through mismatched unrelated donor (MMURD), haploidentical, and cord blood transplantation, emphasizing the data supporting broader access and equitable outcomes across donor types. These presentations chart a bold trajectory for the field, illuminating how scientific innovation,..."

Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Transplantation

Harnessing tumor immune checkpoints for autoimmune disease therapeutics. (PubMed, Front Immunol) - "Clinical success with CTLA-4-Ig (abatacept) and emerging efficacy of PD-1 agonists (e.g., peresolimab) provide proof-of-concept that augmenting inhibitory signaling can ameliorate autoimmunity. Future progress will require multi-omics profiling, biomarker-driven stratification, and next-generation agonist design. IC-targeted strategies hold promises but demand context-aware, mechanistically informed development for broad clinical impact in ADs."

IO biomarker • Journal • Review • Immunology • Oncology • Transplantation • HAVCR2 • LAG3 • PD-1 • TIGIT

Disseminated Histoplasmosis Mimicking Decompensated Cryptogenic Cirrhosis With Portal Hypertension (ACG 2026) - "Case Description/ A 68-year-old woman with rheumatoid arthritis previously treated with abatacept, methotrexate, and hydroxychloroquine and presumed cryptogenic cirrhosis was admitted with markedly elevated liver enzymes and a right frontoparietal subdural hematoma after a ground-level fall...Liposomal amphotericin B was initiated, complicated by SIRS requiring ICU care, then transitioned to oral itraconazole...Figure: Figure 1. Axial CT abdomen demonstrating scattered, small to moderate volume ascites."

Cardiovascular • CNS Disorders • Fibrosis • Gastrointestinal Disorder • Hepatology • Immunology • Infectious Disease • Inflammatory Arthritis • Neuroendocrine Tumor • Portal Hypertension • Rheumatoid Arthritis • Solid Tumor • CHGA

Behind the Rings:â¯Why Histology Is King in Lymphocytic Esophagitis (ACG 2026) - "She was maintained on her immunosuppression (abatacept) and a proton pump inhibitor (PPI), with plan for empiric dilation if dysphagia persists...She failed to improve on PPI and faced compliance and financial barriers, including insurance denial of oral budesonide suspension and non-adherence to fluticasone inhaler, resulting in persistent symptoms and is being switched to Dupilumab...Further studies are needed to elucidate risk factors and tailor guidelines specifically for LE. Figure: Schatzki ring in Case 2 on EGD Figure: Schatzki ring in Case 3 on EGD"

Breast Cancer • Diabetes • Dyspepsia • Eosinophilic Esophagitis • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Immunology • Inflammatory Arthritis • Lupus • Metabolic Disorders • Solid Tumor • Systemic Lupus Erythematosus

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: NYU Langone Health | Not yet recruiting ➔ Recruiting | Trial completion date: Sep 2027 ➔ Jan 2028 | Initiation date: Sep 2025 ➔ Dec 2025 | Trial primary completion date: Sep 2027 ➔ Jan 2028

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Orthopedics • Psoriatic Arthritis • Rheumatology

Risks of breast or prostate cancer recurrence and a second cancer in patients with inflammatory arthritis following treatment with biologic and targeted synthetic DMARDs - A nationwide cohort study (EULAR 2026) - "Eligible drugs included all five TNFi, non-TNFi bDMARDs (abatacept, rituximab, sarilumab, tocilizumab (for RA), sekukinumab, ixekizumab, bimekizumab (for SpA/PsA), and tsDMARDs, that is JAK inhibitors (baricitinib, filgotinib, tofacitinib, upadacitinib). The corresponding analyses of non-TNFi-bDMARDs, and in particular tsDMARDs, were limited by few events. The findings are clinically reassuring, supporting the safety of TNFi when treating IA in patients with a prior breast or prostate cancer."

Clinical • Ankylosing Spondylitis • Breast Cancer • Genito-urinary Cancer • Immunology • Inflammatory Arthritis • Oncology • Prostate Cancer • Psoriatic Arthritis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Solid Tumor • Spondylarthritis

Disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis after failure of biologic or targeted synthetic therapy: a systematic review and network meta-analysis. (PubMed, Cochrane Database Syst Rev) - "We found high-certainty evidence that nine therapies and moderate-certainty evidence that two therapies provide a clinically important benefit in improving disease activity compared to placebo for people with rheumatoid arthritis after failure of b/ts DMARD therapy. There was significant uncertainty surrounding treatment-related harms, with the evidence having been downgraded for serious or extremely serious imprecision. Pair-wise comparisons showed no significant differences among therapies, although the certainty of evidence was low. The lack of clarity regarding safety and comparative efficacy suggests that treatment decisions should be guided by individual patient characteristics and preferences."

Clinical • Journal • Retrospective data • Review • Fatigue • Immunology • Infectious Disease • Inflammatory Arthritis • Oncology • Pain • Rheumatoid Arthritis • Rheumatology • IL6

Risk of Malignant Melanoma with biologic- or targeted synthetic disease-modifying therapies in patients with rheumatoid arthritis: a Swedish Nationwide Cohort Study (EULAR 2026) - "Exposures were categorized as (i) JAKi (baricitinib, filgotinib, upadacitinib, tofacitinib), (ii) non-TNFi (abatacept, rituximab, sarilumab, tocilizumab), and (iii) TNFi (adalimumab, certolizumab, etanercept, golimumab, infliximab). However, for both drug classes there were signals of an internal shift in the distribution of invasive (approximately 1 extra annual case for every 2000 patients) vs. in situ MM (approximately 1 fewer annual case for every 2000 patients). Abatacept was associated with an increased risk of MM overall."

Clinical • Congestive Heart Failure • Coronary Artery Disease • Diabetes • Genetic Disorders • Heart Failure • Immune Modulation • Immunology • Infectious Disease • Inflammatory Arthritis • Melanoma • Metabolic Disorders • Nephrology • Non-melanoma Skin Cancer • Pulmonary Disease • Renal Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Skin Cancer • Solid Organ Transplantation • Solid Tumor

Post-transplant cyclophosphamide, abatacept, and vedolizumab to prevent GVHD after hematopoietic stem cells transplantation in children with acute leukemia: results of a prospective trial. (PubMed, Bone Marrow Transplant) - No abstract available

Journal • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Oncology • Transplantation

Carotid Atherosclerosis Assessed by Ultrasound Predicts Treatment Response to Abatacept in Rheumatoid Arthritis (ACR Convergence 2026) - No abstract available

Atherosclerosis • Cardiovascular • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

The Sjögren's Tool for Assessing Response (STAR) demonstrates its ability to accurately detect treatment efficacy in 17 recent RCTs in Sjögren's disease (ACR Convergence 2026) - P1/2, P2, P2/3, P3 | " The following data were used to assess the performance of 20 STAR candidate options: Data from 9 clinical trials used for STAR development: abatacept (NCT02915159), leflunomide + hydroxychloroquine (REPURPSS-I, EudraCT 2020-001933-11), rituximab (TEARS NCT0074094, TRACTISS ISRCTN65360827), hydroxychloroquine (JOQUER NCT00632866), tocilizumab (NCT01782235), baminercept (NCT01552681), and phase II trials of iscalimab (NCT02291029) and ianalumab (NCT02962895). Data from 7 independent clinical trial datasets (external validation set): belimumab ± rituximab (NCT02631538), abatacept (NCT02915159), anti-IL-7 therapy (NCT04605978), remibrutinib (NCT04035668), iscalimab (NCT03905525, cohorts 1 and 2), leflunomide + hydroxychloroquine (EudraCT 2020-001933-11), and dazodalibep (NCT04129164)... This large number of new trials provided a large amount of data for informing the selection of the final STAR responder index. The STAR 3AV1 where response rely on..."

Clinical • Sjogren's Syndrome • IL7

Combination Therapy with Abatacept and Daratumumab in Patients with Active Rheumatoid Arthritis: Phase I Results of the CURACTA Trial (ACR Convergence 2026) - No abstract available

Clinical • Combination therapy • P1 data • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Comparing Abatacept to Usual Care for Preventing Disease Worsening in Recently Diagnosed Limited Juvenile Idiopathic Arthritis (ACR Convergence 2026) - "Early treatment with abatacept did not reduce disease extension among children with recently diagnosed limited JIA. Rates of progression to polyarthritis or uveitis were comparable and substantially lower than anticipated in all groups. Comparable outcomes among patients treated with abatacept and methotrexate suggest early aggressive treatment with either medication may be associated with favorable outcomes and support the concept of an early therapeutic window in limited JIA."

Gastroenterology • Gastrointestinal Disorder • Idiopathic Arthritis • Immunology • Infectious Disease • Inflammatory Bowel Disease • Novel Coronavirus Disease • Ocular Inflammation • Ophthalmology • Psoriasis • Rheumatology • Uveitis

Comparative Effectiveness of JAK Inhibitors Versus Abatacept in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A National Multicenter Cohort of 667 Patients (ACR Convergence 2026) - No abstract available

Clinical • HEOR • Immunology • Inflammatory Arthritis • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology

Subcutaneous Tocilizumab versus Abatacept in Rheumatoid Arthritis with inadequate response to TNFis: results of the SUNSTAR head-to-head, multicentre, open-label, randomised superiority trial (ACR Convergence 2026) - No abstract available

Clinical • Head-to-Head • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Effect of Nintedanib Associated to Abatacept in Rheumatoid Arthritis-Associated Interstitial Lung Disease. National Multicenter Study of 526 Patients. (ACR Convergence 2026) - No abstract available

Clinical • Immunology • Inflammatory Arthritis • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology

Immunoproteomic Profiling of Abatacept-treated Patients with Limited Juvenile Idiopathic Arthritis (ACR Convergence 2026) - No abstract available

Clinical • Idiopathic Arthritis • Immunology • Rheumatology

Clinical and laboratory manifestations and treatment of children with TNFRSF1A gene variants. (PubMed, World J Clin Pediatr) - "Variants in the TNFRSF1A gene may cause a wide range of clinical symptoms, including eye and intestinal lesions that are not typical of sJIA. All patients with fever and unusual sJIA symptoms should have molecular genetic testing for TNFRSF1A variants to confirm or exclude AID early. Early diagnosis enables timely therapy and prevents complications. Tocilizumab (39.3%), canakinumab (33.3%), and TNF inhibitors (21.2%) achieved remission in children with TNFRSF1A variants. Some patients required multiple bDMARD switches to achieve remission, highlighting the complexity of treatment decisions in this group."

Journal • Amyloidosis • CNS Disorders • Gastrointestinal Disorder • Idiopathic Arthritis • Immunology • Infectious Disease • Inflammation • Oncology • Otorhinolaryngology • Pain • Pediatrics • Rheumatology • Ventriculomegaly • TNFRSF1A

Immune Checkpoint Inhibitor Myocarditis and Myotoxicity. (PubMed, Circulation) - "Corticosteroids are generally recommended; however, severe, progressive, or refractory disease increasingly supports pathophysiology-directed-based therapies, including abatacept and ruxolitinib. Evidence is promising for these therapies but not definitive, pending prospective trials. Rechallenge is often avoided but could be reassessed in selected patients under strict surveillance."

Checkpoint inhibition • IO biomarker • Journal • Review • Cardiovascular • CNS Disorders • Gastrointestinal Disorder • Immunology • Inflammation • Myositis • Oncology • Solid Tumor • Thymoma • Thymus Cancer • CD80

A Review of Modern Therapies and New Innovations in the Treatment of Cutaneous Graft-versus-Host Disease. (PubMed, Dermatol Ther (Heidelb)) - "Recent advances in GVHD management have led to the introduction of targeted systemic agents, such as ruxolitinib, belumosudil, axatilimab, ibrutinib, and abatacept, each addressing different pathways implicated in disease pathogenesis and leading to incorporation into disease management based on established algorithms or select clinical contexts. Additionally, local immunomodulatory therapies, such as topical ruxolitinib, phototherapies, and extracorporeal photopheresis, can be utilized as adjunctive therapies for persistent or localized cutaneous disease. Cellular therapies, specifically mesenchymal stromal cells and regulatory T cells (Treg), are emerging therapies with promising potential in modulating the immune response and improving clinical outcomes. This review summarizes the current standards of care and recent therapeutic advances in the management of cutaneous GVHD, focusing on evidence-based therapies and skin-specific outcomes."

Journal • Review • Bone Marrow Transplantation • Graft versus Host Disease • Immunology • Transplantation

ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis (clinicaltrials.gov) - P2 | N=20 | Suspended | Sponsor: Leland Metheny | Recruiting ➔ Suspended

Trial suspension • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Chronic Myeloid Leukemia • Chronic Myelomonocytic Leukemia • Graft versus Host Disease • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Leukemia • Lymphoma • Myelodysplastic Syndrome • Oncology • Transplantation • CD34 • FLT3

Efficacy and Tolerance of a Combination of Targeted Therapies Indicated for Asthma and Chronic Inflammatory Rheumatism. (PubMed, Joint Bone Spine) - "This is the largest case series to date on dual targeted therapy for CIR and allergic asthma. Rheumatologic control was generally maintained, particularly when rheumatologic treatment was initiated first. Pulmonary infections were the main adverse events, highlighting the need for caution in patients with additional pulmonary comorbidities."

Journal • Ankylosing Spondylitis • Asthma • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Pulmonary Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • IL17A • IL5